Aurinia Pharmaceuticals
AUPH
15 hedge funds and large institutions have $12.8M invested in Aurinia Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
7% more funds holding
Funds holding: 14 → 15 (+1)
3.61% less ownership
Funds ownership: 9.01% → 5.4% (-3.6%)
73% less capital inflows, than outflows
Capital inflows: $3.14M | Capital outflows: $11.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.01M |
| 2 |
SG Americas Securities
New York
|
+$1.01M |
| 3 |
Redmile Group
San Francisco,
California
|
+$429K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$187K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Great Point Partners
Greenwich,
Connecticut
|
-$7.19M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.12M |
| 3 |
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.66M |
| 4 |
Lombard Odier Asset Management (USA)
New York
|
-$283K |
| 5 |
Abingworth
London,
United Kingdom
|
-$200K |
AUPH Hedge Fund Activity: Q3 2016 in Review
15 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2016, worth a combined $12.8M — down 36% from $20.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AUPH positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.01M. The largest seller was Great Point Partners, exiting entirely with an estimated $7.19M sold.
- 15 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2016, up from 14 in Q2 2016.
- Funds reported $12.8M of Aurinia Pharmaceuticals stock for Q3 2016, down 36% quarter-over-quarter.
- 7 funds opened new Aurinia Pharmaceuticals positions in Q3 2016 and 6 closed out, a net change of +1 holder.
- The largest Aurinia Pharmaceuticals buyer in Q3 2016 was Goldman Sachs, an estimated $1.01M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2016 was Great Point Partners, an estimated $7.19M sold.
Based on aggregated 13F filings for Q3 2016.